No Data
No Data
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an
Express News | Dyne Therapeutics Shares Are Trading Higher After JP Morgan Maintained an Overweight Rating on the Stock and Raised Its Price Target From $39 to $43
Dyne Therapeutics Is Maintained at Overweight by JP Morgan
Dyne Therapeutics Is Maintained at Overweight by JP
Dyne Therapeutics Price Target Raised to $43.00/Share From $39.00 by JP Morgan
Dyne Therapeutics Price Target Raised to $43.00/Share From $39.00 by JP
JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating
Dyne Therapeutics (DYN) has an average buy rating and a price target range of $41 to $56, according to analysts polled by Capital IQ.Price: 34.46, Change: +0.84, Percent Change: +2.51